New treatment for rectal cancer offers hope in avoiding surgery

A new treatment for locally advanced rectal cancer shows favorable results in that surgery can sometimes be avoided completely. It also reduces the risk of recurrence. The method has been confirmed as effective in a comprehensive study conducted at Uppsala University and published in eClinicalMedicine.

"The tumor disappears completely more often, thereby increasing the chance of avoiding surgery and retaining normal rectum and rectal function. Moreover, there are fewer metastases," says Bengt Glimelius, Professor of Oncology at Uppsala University and Senior Consultantat Uppsala University Hospital, about the new method.

Rectal cancer affects around 2,000 people in Sweden every year. Of these, a third have a high risk of recurrence. When a person is diagnosed with rectal cancer, part of the bowel is often removed, which could lead to the need for a stoma or problems controlling one's bowels. Patients often first receive radiotherapy or a combination of radiotherapy and concurrent chemotherapy for five weeks, followed by surgery and usually an additional round of chemotherapy for up to six months.

A study conducted by Uppsala University in everyday healthcare shows that it is possible to double the chance of eliminating the need to surgically remove part of the bowel if all radiotherapy and chemotherapy are given first and then the patient undergoes surgery, if necessary.

If the tumor disappears completely during treatment, surgery is not required. This means that the rectum is preserved and the need for a stoma and a new rectum is eliminated. When part of the rectum is surgically removed, the new rectum does not quite understand that it should be able to refrain from frequently sending a signal to the brain that you need to use the toilet."

Bengt Glimelius, Professor of Oncology at Uppsala University and Senior Consultantat Uppsala University Hospital

A large number of doctors, researchers and research nurses have contributed to the study. Patient data was collected for a large number of patients via the Swedish Colorectal Cancer Registry (SCRCR), with 461 patients included.

Locally advanced rectal cancer has traditionally been treated with a combination of radiotherapy and chemotherapy, followed by surgery and further chemotherapy. Four years ago, a randomized study showed that an alternative approach of one week of radiotherapy followed by just over four months of chemotherapy resulted in more tumors disappearing completely and fewer having distant metastases. Later on, however, slightly more local recurrences were observed. Uppsala was the first region to choose to introduce this treatment, but with a shortened chemotherapy period of three months. Several other regions later followed suit.

The new study confirms the results of the previous randomized study, but also that the noted increase in local recurrences was not observed here.

"With the old treatment, the randomized study failed to find any tumor in 14 percent of patients who underwent surgery. The new model doubled that figure to 28 percent. The new Swedish study had the same results, but without an increase in local recurrence rate after almost five years of follow-up. It is important to show that experimental treatments also work in everyday healthcare," says Bengt Glimelius.

Source:
Journal reference:

Glimelius, B., et al. (2024). Total neoadjuvant treatment using short-course radiotherapy and four CAPOX cycles in locally advanced rectal cancer with high-risk criteria for recurrence: a Swedish nationwide cohort study (LARCT-US). eClinicalMedicine. doi.org/10.1016/j.eclinm.2024.102771.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers uncover mechanism fueling prostate cancer